SCHEMBL20266985

SCHEMBL20266985

O=C(O)NCCNC(=O)c1ccc(-c2ccccc2)[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 3/20 0.52
▸ HSD17B10 Q99714 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ PTPN11 Q06124 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HDAC3 O15379 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20267071 0.86 PTPN1 (0.51) PTPN1HSD17B10KDM4EUSP2HPGD
SCHEMBL22307347 0.83 PTPN1 (0.54) PTPN1HSD17B10KDM4EUSP2HPGD
SCHEMBL18493700 0.82 PTPN1 (0.45) PTPN1HSD17B10KDM4EUSP2HPGD
SCHEMBL20287868 0.81 BCHE (0.47) PTPN1POLBMAPTHDAC1
SCHEMBL7185412 0.79 PTPN1 (0.50) PTPN1HSD17B10KDM4EUSP2HPGD
SCHEMBL22040413 0.79 PTPN1 (0.47) PTPN1HSD17B10KDM4EUSP2HPGD
SCHEMBL17210264 0.77 PTPN1 (0.43) PTPN1HSD17B10KDM4EUSP2HPGD
SCHEMBL17267000 0.76 PTPN1 (0.79) PTPN1KDM4ELMNAPOLBPTPN11
SCHEMBL31265773 0.76 PTPN1 (0.85) PTPN1LMNAPOLBPTPN11TP53
SCHEMBL17511039 0.75 RAB9A (0.49) POLBTP53MAPTHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 — — US disclosed
US-20200093852-A1 Methods of Treating Ocular Disorders Beta Therapeutics Pty Ltd (AU) 2020-03-26 — — US disclosed
US-20190345143-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2019-11-14 — — US disclosed
EP-3554505-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2019-10-23 — — EP disclosed
EP-3555071-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty. Ltd. (AU) 2019-10-23 — — EP disclosed
WO-2018107201-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2018-06-21 — — WO disclosed
WO-2018107226-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2018-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093852-A1 Methods of Treating Ocular Disorders ALDH1A2, HPSE, RB1 PTPN1 2814/4885HSD17B10 1474/4885KDM4E 1654/4885
US-20190345143-A1 HEPARANASE INHIBITORS AND USE THEREOF HPSE, HEXD, ENGASE PTPN1 364/4885HSD17B10 1091/4885KDM4E 2390/4885
US-11787783-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE PTPN1 364/4885HSD17B10 1091/4885KDM4E 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback